Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract disease in
young children and elderly people. Although the virus was isolated in 1955, an effective …

Recombinant adeno-associated viral (rAAV) vectors have been used in more than 150
clinical trials with a good safety profile and significant clinical benefit in many genetic …

The volume available in icosahedral virus capsids limits the size of viral genomes. To
overcome this limitation, viruses have evolved strategies to increase their coding capacity by …

Adeno-associated virus (AAV) entry is determined by its interactions with specific surface
glycans and a proteinaceous receptor (s). Adeno-associated virus receptor (AAVR)(also …

The adeno-associated virus type 2 (AAV2) uses heparan sulfate proteoglycan (HSPG) as its
primary cellular receptor. In order to identify amino acids within the capsid of AAV2 that …

Recombinant adeno-associated viral vectors (rAAVs) have been widely used for gene
delivery in animal models, and are currently evaluated for human gene therapy after …

Abstract The Adeno-associated viruses (AAVs) are not associated with any diseases, and
their ability to package non-genomic DNA and to transduce different cell/tissue populations …

In the last two decades, recombinant adeno-associated virus has emerged as the most
popular gene therapy vector. Recently AAV gene therapy has been approved by the FDA for …

The nucleolus is a sub-nuclear body known primarily for its role in ribosome biogenesis.
Increased number and/or size of nucleoli have historically been used by pathologists as a …

Adeno-associated virus (AAV) has attracted considerable interest as a gene therapy vector
over the past decade. In all, 85% of the current 2052 PubMed references on AAV (as of …